In nebuliser therapy, the amount of medication that reaches the lungs is the key factor. This requires nebulisers that can produce sufficiently fine aerosol droplets in as short a time as possible - or in other words, that are as efficient as possible. There is an objective parameter to measure this efficiency – RDDR (Respirable Drug Delivery Rate). It measures the respirable dose per minute (the amount of inhalation solution that reaches the lungs).
The droplets the nebuliser produces from the inhalation solution have to be relatively fine to reach the lungs. Droplets ≤ 5 µm are therefore referred to as respirable particles.
But it is not only the size of the droplets that makes a difference. Finer does not necessarily mean better, but rather it is the amount of the respirable aerosol that reaches the lungs that is important. So it is the RDDR that is actually important – the objective index denoting the efficiency of the inhalation system.
PARI nebulisers are often recommended in the package inserts of medications for inhalation. Thanks to their world-wide availability and high quality, our PARI nebulisers are often used in clinical studies of medications.
Of course, there are other factors that also determine how much aerosol actually reaches the lungs. For example, how patient the adult or child is to carry on the inhalation to the end and whether a mouthpiece or mask is used. However, more respirable particles per time unit also means you need less patience for an effective treatment.
PARI nebulisers have come out top in various comparative studies with commercially available nebulisers for children and adults.1,2
Source: Modified after: Modifiziert nach: Walz-Jung H et al., Pneumologie 2018, 72:820–831
Conclusion: Ensure there is a high RDDR. This means short nebulisation times while delivering high respirable doses of the desired medication into the lungs.
1 Walz-Jung H et al., Pneumologie 2018
2 Walz-Jung H et al., Poster GPP 2013